Soheir S. Adam, MD; Jennifer R. McDuffie, PhD; Thomas L. Ortel, MD, PhD; John W. Williams Jr., MD
Financial Support: By the Veterans Affairs Office of Research and Development, Quality Enhancement Research Initiative (VA-ESP Project 09-010;2012).
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M12-1317.
Requests for Single Reprints: Soheir S. Adam, MD, Duke University Medical Center, Department of Medicine, Box 3939, Durham, NC 27710.
Current Author Addresses: Dr. Adam: Duke University Medical Center, Department of Medicine, Box 3939, Durham, NC 27710.
Dr. McDuffie: Durham Veterans Affairs Medical Center, 411 West Chapel Hill Street, Suite 600, Durham, NC 27701.
Dr. Ortel: Duke University Medical Center, Department of Medicine, Stead Building, Room 0563, 201 Trent Drive, DUHS Box #3422, Durham, NC 27710.
Dr. Williams: Durham Veterans Affairs Medical Center, 411 West Chapel Hill Street, Suite 500, Durham, NC 27701.
Author Contributions: Conception and design: S.S. Adam, J.R. McDuffie, T.L. Ortel, J.W. Williams Jr.
Analysis and interpretation of the data: S. S. Adam, J.R. McDuffie, T.L. Ortel, J.W. Williams Jr.
Drafting of the article: S.S. Adam, J.R. McDuffie.
Critical revision of the article for important intellectual content: S.S. Adam, J.W. Williams Jr.
Final approval of the article: S.S. Adam, J.R. McDuffie, T.L. Ortel, J.W. Williams Jr.
Obtaining of funding: J.W. Williams Jr.
Collection and assembly of data: S.S. Adam, J.R. McDuffie, T.L. Ortel, J.W. Williams Jr.
New oral anticoagulants (NOACs), including direct thrombin inhibitors (DTIs) and factor Xa (FXa) inhibitors, are emerging alternatives for prophylaxis and treatment of atrial fibrillation (AF) and venous thromboembolism (VTE).
To compare the benefits and harms of NOACs versus warfarin for AF and VTE.
MEDLINE, EMBASE, and the Cochrane Database of Systematic Reviews from January 2001 through July 2012; U.S. Food and Drug Administration (FDA) database for adverse event reports.
English-language, randomized, controlled trials (RCTs) comparing NOACs with warfarin for management of AF or VTE and observational studies and FDA reports on adverse effects.
Two independent reviewers abstracted data and rated study quality and strength of evidence.
Six good-quality RCTs compared NOACs (2 DTI studies, 4 FXa inhibitor studies) with warfarin. In AF, NOACs decreased all-cause mortality (risk ratio [RR], 0.88 [95% CI, 0.82 to 0.96]); in VTE, NOACs did not differ for mortality or VTE outcomes. Across indications, adverse effects of NOACs compared with warfarin were fatal bleeding (RR, 0.60 [CI, 0.46 to 0.77]), major bleeding (RR, 0.80 [CI, 0.63 to 1.01]), gastrointestinal bleeding (RR, 1.30 [CI, 0.97 to 1.73]), and discontinuation due to adverse events (RR, 1.23 [CI, 1.05 to 1.44]). Subgroup analyses suggest a higher risk for myocardial infarction with DTIs than with FXa inhibitors. Bleeding risk for NOACs may be increased in persons older than 75 years or those receiving warfarin who have good control.
There were no head-to-head comparisons of NOACs and limited data on harms.
New oral anticoagulants are a viable option for patients receiving long-term anticoagulation. Treatment benefits compared with warfarin are small and vary depending on the control achieved by warfarin treatment.
Department of Veterans Affairs.
Adam SS, McDuffie JR, Ortel TL, et al. Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic Review. Ann Intern Med. 2012;157:796–807. doi: https://doi.org/10.7326/0003-4819-157-10-201211200-00532
Download citation file:
Published: Ann Intern Med. 2012;157(11):796-807.
Cardiology, High Value Care, Rhythm Disorders and Devices, Venous Thromboembolism.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use